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Original Article
The emergence of accurate and easy-to-use continuous glu-
cose monitoring (CGM) devices, which enable users to 
view in real-time estimates of plasma glucose and receive 
alarms for impending hypo- or hyperglycemia, is a major 
step toward improved glucose monitoring and facilitates 
appropriate changes to insulin therapy. CGM is becoming 
increasingly popular in people with type 1 diabetes across 
all age-groups.1 Clinical benefits, particularly in combina-
tion with insulin pump therapy, are conditioned on good 
adherence.2,3
CGM-assisted therapeutic approaches beyond diabetes 
monitoring include threshold-suspend and predictive low glu-
cose management insulin pump therapy, which temporarily 
interrupt insulin delivery at predefined low sensor glucose 
levels, and thus may alleviate the burden of hypoglycemia.4,5 
Closed-loop (CL) systems expand on the concept of sensor 
responsive insulin delivery using a control algorithm that 
autonomously modulates insulin delivery below and above 
preset insulin pump delivery based on real-time sensor glu-
cose levels.6 CL approaches are increasingly tested in outpa-
tient and home settings.7-11
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Abstract
Background: Closed-loop (CL) systems direct insulin delivery based on continuous glucose monitor (CGM) sensor values. 
CGM accuracy varies with sensor life, being least accurate on day 1 of sensor insertion. We evaluated the effect of sensor 
life (enhanced Enlite, Medtronic MiniMed, Northridge, CA) on overnight CL.
Methods: In an open-label, randomized, 2-period, inpatient crossover pilot study, 12 adolescents on insulin pump (age 
16.7 ± 1.9 years; HbA1c 66 ± 10 mmol/mol) attended a clinical research facility on 2 overnight occasions. In random order, 
participants received CL on day 1 or on day 3-4 after sensor insertion. During both periods, glucose was automatically 
controlled by a model predictive control algorithm informed by sensor glucose. Plasma glucose was measured every 30 to 
60 min.
Results: During overnight CL (22:30 to 07:30), the proportion of time with plasma glucose readings in the target range (3.9-
8.0 mmol/l, primary endpoint) when initiated on day 1 of sensor insertion vs day 3-4 were comparable (58 ± 32% day 1 vs 
56 ± 36% day 3-4; P = .34), and there were no significant differences between interventions in terms of mean plasma glucose 
(P = .26), percentage time above 8.0 mmol/l (P = .49), and time spent below 3.9 mmol/l (P = .93). Sensor accuracy varied with 
sensor life (mean absolute relative difference 19.8 ± 15.0% on day 1 and 13.7 ± 10.2% on day 3 to 4). Sensor glucose tended 
to under-read plasma glucose inflating benefits of CL on glucose control.
Conclusions: In spite of differences in sensor accuracy, overnight CL glucose control informed by sensor glucose on day 
1 or day 3-4 after sensor insertion was comparable. The model predictive controller appears to mitigate against sensor 
inaccuracies.
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Glucose control during CL application depends to a large 
extend on the accuracy and reliability of CGM systems. 
CGM accuracy and reliability has improved due to advances 
in sensor technology, data processing and calibration algo-
rithms.12,13 However, consistent glucose sensor function over 
the full lifetime of a sensor may be unattainable and sensors 
are least accurate in the 24-hour period immediately postin-
sertion compared to half-way through sensor life (say days 3 
to 4).14,15 This may relate to insertion trauma causing onset of 
an inflammatory response and tissue microhemorrhage 
which may resolve with time.16-18
The purpose of the present study was to evaluate the effect 
of sensor life on CL performance comparing CL efficacy and 
safety on day 1 of sensor insertion to day 3 to 4 of sensor 
insertion in young people with type 1 diabetes over an over-
night period at a clinical research facility. We hypothesized 
that more accurate sensor performance as usually seen half-
way through sensor life, may lead to better CL performance 
as assessed by frequent plasma glucose measurements.
Methods
An open label randomized 2-period crossover study com-
pared overnight CL insulin delivery on day 1 of sensor inser-
tion versus day 3 to 4 of sensor insertion. The study was 
designed as a pilot trial. Prior to study initialization, approval 
was sought and received from the local independent research 
ethics committee and the UK regulatory authority (Medicines 
& Health products Regulatory Agency). Participants aged 
≥16 years and parents or guardians of participants aged <16 
years signed informed consent; written assent was obtained 
from minors.
Subjects and Study Protocol
The study was conducted at the Wellcome Trust Clinical 
Research Facility at Addenbrooke’s Hospital, Cambridge, 
between May 2014 and April 2015. Children and adolescents 
aged 6-18 years were recruited from 3 pediatric diabetes 
clinics at Cambridge, London University College Hospital, 
and Peterborough. Eligibility criteria included type 1 diabe-
tes (WHO criteria) for at least 12 months, insulin pump ther-
apy for at least 3 months, glycated hemoglobin (HbA1c) 
below 97 mmol/mol (11%) based on analysis from local 
laboratory within 3 months. Exclusion criteria included any 
physical or psychological disease likely to interfere with the 
normal conduct of the study and data interpretation or cur-
rent treatment with drugs likely to interfere with glucose 
metabolism.
Medtronic MiniMed Paradigm® Veo™ insulin pumps 
(MMT-554 or MMT-754) with second-generation Enlite™ 
CGM sensors (Medtronic MiniMed, Northridge, CA, 
USA) were used as study pump and continuous glucose 
monitoring systems (CGM). At recruitment, participants 
received training on real-time CGM component of the Veo 
system, and participants’ competency in using CGM was 
assessed and documented by the clinical investigators. No 
additional pump training was provided as all participants 
recruited for this trial were already using Veo insulin pump 
prior to enrolment. CGM calibration followed manufac-
turer’s instructions using finger-stick glucose measure-
ments taken every 12 h on CONTOUR XT Meter (Bayer, 
Leverkusen, Germany) which was checked for accuracy by 
calibration fluid.
Participants attended the clinical research facility for 2 
overnight periods, 2 to 6 weeks apart, with identical study 
protocol performed on both occasions. On 1 occasion, the CL 
system was informed by a glucose sensor inserted in the 
morning of the study visit, and on the other occasion study 
participants had been fitted with a CGM sensor 3 to 4 days 
prior to the study visit. The order of the interventions was 
random according to a computer-generated allocation 
sequence with permuted blocks (Figure 1).
On each occasion, participants were admitted at 17:00 
and stayed until 08:00 the following day (Figure 2). An 
intravenous cannula was placed for blood sampling starting 
at 18:00. Participants consumed an evening meal at 18:30 
(74 ± 27 g carbohydrates) and an optional bedtime snack at 
21:00 (23 ± 15 g carbohydrates). The meals and snacks were 
identical on the 2 occasions. Meals and carbohydrate con-
tent were chosen by the children and their families based on 
individual preferences and reflecting usual practice at home. 
Figure 1. Study design.
Figure 2. Schematic presentation of overnight study visit 
schedule. Identical procedures were followed during both study 
visits.
Tauschmann et al 3
Meals were accompanied by insulin boluses calculated 
using participants’ standard insulin pump bolus calculator 
settings and premeal finger-stick glucose levels. Rapid act-
ing insulin analogue aspart (Novo Nordisk, Bagsvaerd, 
Denmark) was used.
CL System
The Amber system Android CL platform employed an 
Android smartphone (Nexus 4, LG, South Korea) running a 
model predictive control algorithm (version 0.3.30, 
University of Cambridge) embedded in user interface mod-
ule and communicating with a Bluetooth to radiofrequency 
translator module linked to Veo pump (all Medtronic 
MiniMed; Figure 3). Every 15 min, the control algorithm 
automatically initiated a new insulin infusion rate based on 
sensor glucose through wireless communication. The calcu-
lations utilized a compartment model of glucose kinetics 
describing the effect of rapid-acting insulin analogues and 
the carbohydrate content of meals on glucose levels. The 
control algorithm was initialized by downloading prepro-
grammed basal insulin doses from the pump. In addition, 
information about participant’s weight and total daily insulin 
dose were entered at setup. No plasma glucose data were 
provided to the algorithm.
Sampling and Assays
For the measurement of glucose and insulin concentration, 
venous blood samples were obtained every 30 minutes until 
23:30, then hourly from 23:30 to 07:30. Plasma was separated 
by centrifugation immediately. Plasma glucose levels were 
determined in real time by YSI2300 STAT Plus analyzer 
(Yellow Springs Instrument, Farnborough, UK) but were not 
used to inform the algorithm. Plasma insulin concentration 
was measured by immunochemiluminometric assay (IV2-
001; Invitron Ltd, Monmouth UK) with an interassay varia-
tion of 7.1%, 2.4% and 7.1% at 89 pmol/L, 488 pmol/L, and 
873 pmol/L, and an analytical sensitivity of 0.12 pmol/L.
Study Outcomes
The primary outcome was the time during CL when plasma 
glucose levels were within the target range from 3.9 to 8.0 
mmol/l in the overnight period from 22:30 until 07:30 on the 
following day.
Secondary outcomes included mean plasma glucose lev-
els, glucose variability, time spent below and above the tar-
get range during observation period (22:30 to 07:30). All 
glucose outcomes were also compared with CGM sensor 
values. Glucose variability was assessed by the standard 
deviation and the coefficient of variation. Hypoglycemia 
burden was assessed by calculating the glucose area under 
the curve less than 3.5 mmol/l. Insulin delivery amounts 
were reported as total overnight basal insulin delivery. Sensor 
accuracy for each study arm was assessed using paired sen-
sor and plasma glucose points. The bias (sensor minus 
plasma value) and relative absolute difference (RAD) (abso-
lute difference divided by the reference value, expressed as 
percentage) were computed for each pair. Numerical accu-
racy outcomes were calculated across the whole range of 
measured glucose levels, as well as for euglycemic (3.9-10.0 
mmol/L), hypoglycemic (<3.9 mmol/L), and hyperglycemic 
(>10.0 mmol/L) ranges stratified according to plasma glu-
cose measurements. Clinical accuracy was assessed by 
Clarke error grid analysis.
Statistical Analysis
The statistical analysis plan was agreed on by investigators 
in advance. All analyses were undertaken on an intention-to-
treat basis. The respective values obtained during the 2 over-
night randomized interventions were compared using a 
least-square regression model. Glucose outcomes and insulin 
outcomes were adjusted for period effect. Rank normal 
transformation analyses were used for highly skewed end-
points. Outcomes were presented as mean ± SD for normally 
distributed values or as median (interquartile range) for non-
normally distributed values. Accuracy outcomes were sum-
marized using descriptive statistics. Efficacy and accuracy 
metrics were calculated by GStat software (University of 
Cambridge, version 2.2), and statistical tests were carried out 
using SPSS software (IBM Software, Hampshire, UK ver-
sion 21). A 5% significance level was used to declare statisti-
cal significance for all comparisons. All P values are 2-sided.
Results
Participants
We approached 15 patients with type 1 diabetes, of whom 13 
participants consented. One participant dropped out during 
run-in (loss to follow-up). In all, 12 subjects were random-
ized, completed both study periods, and provided data for 
analyses (Table 1).
Figure 3. Amber CL platform comprising Android phone 
running the model predictive control algorithm, translator 
facilitating wireless communication between the phone and the 
Veo pump, and CGM transmitter connected to Enlite sensor.
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Overnight Glucose Control
Study outcomes during the overnight CL periods (22:30 to 
07:30) are summarized in Table 2. Plasma glucose and sen-
sor glucose profiles during CL on day 1 and day 3 to 4 after 
sensor insertion are shown in Figure 4.
Plasma Glucose Outcomes
Plasma glucose levels remained within the target range of 3.9 
to 8.0 mmol/l (primary endpoint) for 58% and 56% of the 
time, respectively, when CL was applied on day 1 or on day 
3 to 4 (P = .30, Table 2). No difference was found in the 
mean plasma glucose concentration (7.9 ± 1.6 vs 7.8 ± 1.8 
mmol/l, P = .26). Proportion of time when plasma glucose 
was in hypoglycemic range (below 3.9 mmol/l) and the area 
under the curve when plasma glucose was less than 3.5 
mmol/l were very low and comparable during the study peri-
ods. There was no difference in glucose variability between 
study periods as measured by the standard deviation and 
coefficient of variation of plasma glucose.
Sensor Glucose Outcomes
The proportion of time that sensor glucose was in the target 
glucose range 3.9 to 8.0 mmol/l during CL was comparable 
on day 1 and day 3 to 4 of sensor use (73 ± 25% vs 71 ± 21%, 
P = .72; Table 2). Similarly, there was no difference in mean 
sensor glucose levels, the proportion of time above and 
below the target range, and variability in glucose readings 
during the 2 overnight study periods (Table 2).
Plasma vs Sensor Glucose
Despite similar CL outcomes between interventions, direct 
comparison of sensor glucose readings and plasma glucose 
derived indices showed marked differences (Table 2). The 
proportion of time spent in target range 3.9 to 8.0 mmol/l was 
significantly higher when calculations were based on sensor 
readings than plasma glucose based calculations (P = .014). 
Mean sensor glucose levels were significantly lower than 
mean plasma glucose readings (P = .010) as was time spent 
above target range (P = .005).
Insulin Delivery
Total overnight insulin delivery (22:30 to 07:30) did not dif-
fer between interventions (8.4 [6.0 to 14.4]U on day 1 of 
sensor insertion vs 11.3 [8.8 to 15.3]U on day 3 to 4, of sen-
sor insertion vs 11.3 [8.8 to 15.3]U on day 3 to 4, P = .13), 
and resulted in similar plasma insulin levels (Figure 5). 
Variability in insulin delivery was similar during the 2 over-
night visits (SD 0.7 [0.6 to 1.0]U vs 0.8 [0.6 to 0.9]U, P = 
.84).
Sensor Accuracy
Sensor accuracy evaluation is summarized in Table 3. On the 
CL nights between 22:30 and 07:30, 126 sensor–plasma glu-
cose pairs were analyzed on day 1 after sensor insertion, and 
123 on day 3 to 4. Across the whole glucose range, numerical 
sensor accuracy expressed as mean ARD was 19.8 ± 15.0% 
on day 1 and 13.7 ± 10.2% on day 3 to 4, respectively (sepa-
rate sensor performance matrices for euglycemic, hypo-and 
hyperglycemic ranges are shown in Table 3). Mean bias for 
sensors on day 1 was -0.9 ± 1.9 mmol/l, and -0.7 ± 1.4 mmol/l 
on day 3 to 4, respectively. On day 1 of insertion the new 
generation Enlite sensor had 96.8% of measurements in 
Clarke error grid zones A+B (zone A, 61.9%; zone B, 34.9%; 
zone C, 0%; zone D, 3.2%; zone E, 0%; Table 3 and Figure 
6). On day 3 to 4, 98.3% of paired sensor data points were in 
zones A+B (zone A, 71.5%; zone B, 26.8%; zone C, 0%; 
zone D, 1.6%; zone E, 0%) (Table 3 and Figure 6).
Discussion
We document that overnight CL glucose control using a 
model predictive control algorithm informed by sensor glu-
cose on day 1 after insertion was similar to that achieved 
when CL was initiated on day 3 to 4 of sensor life. Glucose 
levels were maintained between 3.9 and 8.0 mmol/l for a 
similar proportion of time, mean plasma glucose readings 
were comparable, and there were no differences in hypogly-
cemia burden.
We observed sensor accuracy comparable to previously 
reported data,14,15,19-21 including reduced accuracy on day 1 of 
sensor insertion.14,15,21 Notwithstanding the reduced accuracy 
on day 1, sensor life did not affect performance of our CL sys-
tem. We hypothesized that this is related to the robustness of 
our model predictive algorithm, which mitigates against sen-
sor inaccuracy and has been safely and effectively used in a 
range of populations and settings including pregnant women, 
adults, adolescents and children in unsupervised home appli-
cation.10,22,23,24 The relatively slow kinetics of subcutaneous 
insulin may inherently increase robustness of CL algorithms 
Table 1. Baseline Characteristics of Study Participants.
Subjects (n) 12
Female (n) 3
Age (years) 16.7 ± 1.9
Weight (kg) 68.6 ± 16.8
BMI (kg/m2) 21.6 ± 3.3
BMI z-score 0.26 ± 1.26
Duration of diabetes (years) 8.7 ± 3.6
Duration of pump use (years) 6.0 ± 2.7
Total daily insulin dose (U/kg/day) 0.90 ± 0.29
Glycated hemoglobin (%) 8.3 ± 1.1
Glycated hemoglobin (mmol/mol) 66 ± 10
Values are mean ± SD, unless otherwise noted.
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as short-lived aberrations in sensor glucose on day 1, translat-
ing to short-term deviations from ideal insulin delivery, may 
have limited impact on glucose control as these insulin deliv-
ery errors cancel each other. However, prolonged sensor inac-
curacies cannot be accommodated in this fashion.
Outcomes based on sensor readings significantly inflated 
CL performance compared to plasma glucose outcomes. 
This is in contrast to findings from an overnight inpatient 
study with a similar design conducted in young children 
using another sensor make, when plasma and sensor based 
Figure 4. Median (interquartile range) of plasma glucose (top panel) and sensor glucose (bottom panel) during overnight closed loop on 
day 1 of sensor insertion (solid red line and red shaded area) and closed loop on day 3 to 4 of sensor insertion period (dashed black line 
and gray shaded area). The glucose range 3.9 to 8.0 mmol/l is denoted by horizontal dashed lines.
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outcomes were comparable.25 In the present study, sensor 
reported glucose levels significantly lower than plasma glu-
cose values. A similar trend was described by Calhoun 
et al.15 In view of these results, previously reported glucose 
outcomes based on Enlite sensor, including to benefits of 
sensor-based therapy regimen (eg, sensor-augmented pump 
therapy, low glucose suspension, CL trials), should be inter-
preted with caution.
The current study was limited by the relatively small sam-
ple size and short overnight intervention periods. A limited 
Figure 5. Insulin infusion rates (top panel), and plasma insulin (bottom panel) are shown for closed loop on day 1 of sensor insertion 
(solid red line and red shaded area) and closed loop on day 3 to 4 of sensor insertion (black dashed line and gray shaded area 
[interquartile range]). The vertical dashed line indicates when closed loop started and the evening meal was consumed.
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number of data points for sensor accuracy assessment were 
collected, particularly with respect to the hypoglycemic range. 
The strengths of our study included the crossover randomized 
design, and the controlled environment to exclude potential 
confounders with respect to this particular research question.
In conclusion, overnight CL glucose control in adolescents 
informed by Enlite glucose sensor on day 1 or day 3 to 4 after 
sensor insertion was comparable. The model predictive con-
troller appears to mitigate against sensor inaccuracies.
Abbreviations
CGM, continuous glucose monitoring; CL, closed loop; HbA1c, 
glycated hemoglobin A1c; RAD, relative absolute difference; 
WHO, World Health Organization.
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CL on day 1 of sensor insertion (n = 12) CL on day 3 to 4 of sensor insertion (n = 12)
Number of paired points 126 123
Mean plasma glucose (mmol/l) 7.9 ± 1.6 7.8 ± 1.8
Clarke error grid (%)
 Zone A 61.9 71.5
 Zone B 34.9 26.8
 Zone C 0 0
 Zone D 3.2 1.6
 Zone E 0 0
Median bias (mmol/l) –0.6 (–1.6 to 0.4) –0.2 (–1.7 to 0.3)
Mean bias (mmol/l) –0.9 ± 1.9 –0.7 ± 1.4
Whole range (2.2-17.9 mmol/l)
 Median AD (mmol/l) 1.1 (0.5 to 1.8) 0.8 (0.3 to 1.7)
 Median ARD (%) 16.3 (7.5 to 28.6) 12.6 (4.7 to 20.9)
 Mean AD (mmol/l) 1.5 ± 1.5 1.1 ± 1.0
 Mean ARD (%) 19.8 ± 15.0 13.7 ± 10.2
Euglycemia (3.9-8.0 mmol/l)
 Number of paired points 71 (56%) 64 (52%)
 Median ARD (%) 12.9 (7.5 to 28.5) 8.5 (4.2 to 16.9)
Hypoglycemia (<3.9 mmol/l)
 Number of paired points 8 (6%) 6 (5%)
 Median ARD (%) 37.0 (31.0 to 40.2) 8.5 (5.0 to 17.8)
Hyperglycemia (>8.0 mmol/l)
 Number of paired points 47 (37%) 64 (43%)
 Median ARD (%) 20.0 (7.4 to 37.4) 18.6 (7.0 to 25.2)
AD, absolute difference; ARD, absolute relative difference; bias, plasma glucose minus sensor glucose.
Values are mean ± SD or median (interquartile range).
Figure 6. Clarke error grid of sensor and plasma glucose levels 
shown for CL on day 1 of sensor insertion (red dots) and CL on 
day 3 to 4 of sensor insertion (gray dots). Data collected from 
22:30 to 07:30 are presented.
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